ClinicalTrials.gg
CompletedNCT03444402Updated May 24, 2018

A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects

A Phase 1 interventional study of CKD-381(formulation I) and CKD-381(formulation II) in GERD, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-24.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.

Enrollment
61st of 66
18 · median 125
Started
2018
with 1 other
Phase 1
6 of 67
none open now
Registered
59th of 67
by date
Lead sponsor
1 of 67
Chong Kun Dang Pharmaceutical

Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 61st largest by enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2018, is one of 6 in phase 1, and was the 59th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 19 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing esomeprazole in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

A Study to compare pharmacokinetics and safety of CKD-381 and D026 in healthy male subjects

Read the detailed description

A randomized, open-label, multiple-dose, and three-way cross over clinical trial to compare pharmacokinetics and safety of CKD-381 and D026 in healthy male subjects

03

Conditions studied

  • GERD

Keywords

  • CKD-381
  • Nexium
04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between 19 aged and 50 aged in healthy male adult
  2. Body weight more than 55kg
  3. more than 18.5 and under 25

Exclusion criteria

Exclusion Criteria:

  1. Have disease that hepatobiliary system, kidney, nervous system, immune system, respiratory system, endocrine system, hemato-oncology disease, cardiovascular system or mental illness, or a history of mental disease.
  2. Have a gastrointestinal disease history that can effect drug absorption or surgery.
  3. reaction or clinically significant hypersensitivity reaction in the history of Esomeprazole, additives or benzimidazole family.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Group A

    Period 1: Test drug(CKD-381 formulation I), Period 2: Test drug(CKD-381 formulation II), Period 3: Reference drug(D026)

    Drug: CKD-381(formulation I) · Drug: CKD-381(formulation II) · Drug: D026(Nexium 40mg)

  • Experimental
    Group B

    Period 1: Test drug(CKD-381 formulation II), Period 2: Reference drug(D026), Period 3: Test drug(CKD-381 formulation I)

    Drug: CKD-381(formulation I) · Drug: CKD-381(formulation II) · Drug: D026(Nexium 40mg)

  • Experimental
    Group C

    Period 1: Reference drug(D026), Period 2: Test drug(CKD-381 formulation I), Period 3: Test drug(CKD-381 formulation II)

    Drug: CKD-381(formulation I) · Drug: CKD-381(formulation II) · Drug: D026(Nexium 40mg)

Interventions

06

What researchers measure

Primary outcomes

  1. AUCtau,ss(Area under the plasma drug concentration-time curve within a dosing interval at steady state)

    Evaluation PK esomeprazole after multiple dose

    Time frame: 0~24h

Secondary outcomes

  1. Cmax,ss(Maximum concentration of drug in plasma at steady state)

    Evaluation PK esomeprazole after multiple dose

    Time frame: 0~24h

  2. Tmax,ss(Time to maximum plasma concentration at steady state)

    Evaluation PK esomeprazole after multiple dose

    Time frame: 0~24h

  3. t1/2(Terminal elimination half-life)

    Evaluation PK esomeprazole after multiple dose

    Time frame: 0~24h

  4. R(Accumulation ratio)

    Evaluation PK esomeprazole after multiple dose

    Time frame: 0~24h

  5. CLss/F(Apparent Clearance at steady state)

    Evaluation PK esomeprazole after multiple dose

    Time frame: 0~24h

  6. Vss/F(Apparent Volume of distribution at steady state)

    Evaluation PK esomeprazole after multiple dose

    Time frame: 0~24h

  7. Cmax(Maximum concentration of drug in plasma)

    Evaluation PK esomeprazole after single dose

    Time frame: 0~24h

  8. AUClast(Area under the plasma drug concentration-time curve from 0 to last)

    Evaluation PK esomeprazole after single dose

    Time frame: 0~24h

  9. Tmax(Time to maximum plasma concentration)

    Evaluation PK esomeprazole after single dose

    Time frame: 0~24h

  10. t1/2(Terminal elimination half-life)

    Evaluation PK esomeprazole after single dose

    Time frame: 0~24h

  11. CL/F(Apparent clearance)

    Evaluation PK esomeprazole after single dose

    Time frame: 0~24h

  12. Vd/F(Apparent volume of distribution)

    Evaluation PK esomeprazole after single dose

    Time frame: 0~24h

07

Study locations

1 site
  • Seoul University Hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in May 2018, 2 months.

Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 2 months is below that.

Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2018
First posted
Feb 23, 2018
StartActual
Mar 2, 2018
Primary completionActual
May 4, 2018
CompletionActual
May 4, 2018
Last update
May 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03444402
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Mar 2, 2018
Primary completion
May 4, 2018
Completion
May 4, 2018
Last update
May 24, 2018

Study contacts

Kyung Sang Yu, M.D
principal investigator · Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CKD-381 · Esomeprazole

Start the discussion